Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Steiner

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Urologie (Heidelberg, Germany)|October 9, 2025
[Self-critical, multicenter analysis of treatment and coding quality using the example of nephroureterectomy on the basis of billing data]Nici Markus Dreger, Christine Lenhart, Friedrich-Carl von Rundstedt, et al.
Elife|May 9, 2023
The large GTPase Sey1/atlastin mediates lipid droplet- and FadL-dependent intracellular fatty acid metabolism of <i>Legionella pneumophila</i>Dario Hüsler, Pia Stauffer, Bernhard Keller, et al.
Onkologie|March 15, 2013
Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional studyLothar Bergmann, Peter J Goebell, Ulrich Kube, et al.
JAMA Oncology|May 9, 2024
Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical TrialMarc-Oliver Grimm, Martin Schostak, Christine Barbara Grün, et al.
World Journal of Urology|February 11, 2020
Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatmentRebecca Roth, Sebastian Dieng, Alisa Oesterle, et al.
World Journal of Urology|September 26, 2019
Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancerNora Tabea Sibert, Sebastian Dieng, Alisa Oesterle, et al.
Journal of Patient-Reported Outcomes|July 15, 2020
A multicenter paper-based and web-based system for collecting patient-reported outcome measures in patients undergoing local treatment for prostate cancer: first experiencesChristoph Kowalski, Rebecca Roth, Günther Carl, et al.
European Urology|September 27, 2023
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)Viktor Grünwald, Philipp Ivanyi, Stefanie Zschäbitz, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|July 25, 2016
Commentaries on Viewpoint: Time for a new metric for hypoxic dose?Grégoire P Millet, Franck Brocherie, Olivier Girard, et al.
Urologie (Heidelberg, Germany)|September 25, 2023
[Urinary incontinence after radical prostatectomy for prostate cancer-data from 17,149 patients from 125 certified centers]Christoph Kowalski, Nora Tabea Sibert, Peter Hammerer, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Urologie (Heidelberg, Germany)|October 9, 2025
[Self-critical, multicenter analysis of treatment and coding quality using the example of nephroureterectomy on the basis of billing data]Nici Markus Dreger, Christine Lenhart, Friedrich-Carl von Rundstedt, et al.
Elife|May 9, 2023
The large GTPase Sey1/atlastin mediates lipid droplet- and FadL-dependent intracellular fatty acid metabolism of <i>Legionella pneumophila</i>Dario Hüsler, Pia Stauffer, Bernhard Keller, et al.
Onkologie|March 15, 2013
Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional studyLothar Bergmann, Peter J Goebell, Ulrich Kube, et al.
JAMA Oncology|May 9, 2024
Nivolumab + Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical TrialMarc-Oliver Grimm, Martin Schostak, Christine Barbara Grün, et al.
World Journal of Urology|February 11, 2020
Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatmentRebecca Roth, Sebastian Dieng, Alisa Oesterle, et al.
World Journal of Urology|September 26, 2019
Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancerNora Tabea Sibert, Sebastian Dieng, Alisa Oesterle, et al.
Journal of Patient-Reported Outcomes|July 15, 2020
A multicenter paper-based and web-based system for collecting patient-reported outcome measures in patients undergoing local treatment for prostate cancer: first experiencesChristoph Kowalski, Rebecca Roth, Günther Carl, et al.
European Urology|September 27, 2023
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)Viktor Grünwald, Philipp Ivanyi, Stefanie Zschäbitz, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|July 25, 2016
Commentaries on Viewpoint: Time for a new metric for hypoxic dose?Grégoire P Millet, Franck Brocherie, Olivier Girard, et al.
Urologie (Heidelberg, Germany)|September 25, 2023
[Urinary incontinence after radical prostatectomy for prostate cancer-data from 17,149 patients from 125 certified centers]Christoph Kowalski, Nora Tabea Sibert, Peter Hammerer, et al.
Pageof 8